SCYX SCYX
Company Profile ↓Company Overview
SCYX (SCYX) is a publicly traded company listed on with a market capitalization of $28.08M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $20.60M (+449.9% YoY); net profit $-8.61M.
- Trailing 12 Months Year-on-year growth — revenue +450.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 1.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 1.84% |
| 1 Year: | 449.95% |
Stock Price Performance
| 1 Year: | -5.29% |
| 6 Months: | -14.80% |
| 3 Months: | -31.60% |
| 1 Month: | +11.93% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)61.93 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 45.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 64.00K | 64.00K | 64.00K | 64.00K | 64.00K | 64.00K | 57.00K | 0 | 0 | 0 | 0 | 12.05M | 0 | 516.00K | 687.00K | 1.32M | 1.56M | 1.13M | 131.45M | 1.76M | 1.37M | 736.00K | 660.00K | - | 257.00K | 1.36M | 334.00K | 18.65M | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | - | - |
| Gross Profit | 462.00K | 720.00K | 66.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 977.00K | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.87M | 10.93M | 8.74M | 8.12M | 16.94M |
| Operating Income | -4.01M | -4.54M | -5.93M | -6.49M | -7.54M | -8.39M | -7.21M | -8.27M | -6.71M | -5.63M | -6.02M | -6.75M | -6.40M | -7.23M | -7.66M | -6.30M | -11.86M | -11.20M | -11.76M | -12.48M | -11.83M | -11.51M | -1.59M | -17.51M | -19.44M | -19.74M | -21.74M | -21.80M | -10.68M | 116.51M | -10.10M | -9.51M | -9.24M | -10.32M | - | -8.61M | -9.56M | -8.40M | 10.52M | -16.94M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.22M | -6.88M | -8.59M | 12.26M | -21.30M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 173.00K | 0 | 0 | 0 | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.39M | -6.88M | -8.59M | 12.26M | -21.30M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.00K | 0 | 0 | 0 | 0 | - |
| Net Income | 2.23M | -3.80M | -6.38M | -9.50M | -8.36M | - | -7.18M | -8.13M | -11.23M | - | -4.87M | -4.20M | -8.40M | -4.00M | -10.76M | 351.00K | -22.91M | -8.40M | -7.94M | -7.00M | -6.38M | 909.00K | -4.68M | 1.66M | -605.00K | -5.45M | -13.35M | -29.58M | -33.88M | 122.26M | -1.76M | 411.00K | -14.46M | -2.81M | - | -5.39M | -6.88M | -8.59M | 12.26M | -21.30M |
| Diluted EPS | -0.98 | -0.45 | -0.75 | -0.78 | -0.60 | - | -0.52 | - | - | - | -0.25 | - | -0.31 | -0.12 | - | 0.01 | - | - | -1.45 | -0.72 | -0.64 | -0.28 | -0.23 | -0.22 | -0.06 | -0.18 | -0.31 | -0.62 | -0.71 | 2.46 | -0.04 | 0.01 | -0.30 | -0.06 | - | -0.88 | -1.12 | -1.36 | - | -3.36 |
| R&D Expense | 1.82M | 2.48M | 3.79M | 3.28M | 3.46M | - | 4.74M | 6.66M | 4.89M | - | 4.02M | 4.45M | 4.46M | 5.33M | 5.60M | 3.93M | 9.68M | 8.47M | 9.28M | 9.87M | 8.47M | 8.03M | 6.95M | 4.73M | 4.40M | 5.74M | 7.13M | 6.43M | 6.83M | 7.04M | 6.47M | 7.21M | 6.81M | 8.07M | - | 5.14M | 7.14M | 5.45M | - | 12.35M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.86M | 1.26M | 257.00K | 257.00K | 257.00K | 257.00K | 121.00K | 0 | - | 5.09M | 140.14M | 3.75M | 20.60M |
| Cost of Revenue | - | - | - | - | - | - | - | - | 312.00K | 628.00K | 15.62M | 0 | - |
| Gross Profit | 552.00K | 3.58M | - | - | - | - | - | - | 12.85M | 4.46M | 124.52M | 3.75M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 90.22M | 51.85M | 40.86M | 36.67M |
| Operating Income | -7.20M | -14.65M | -28.35M | -27.82M | -26.32M | -29.98M | -48.92M | -51.15M | - | -85.76M | 72.67M | -37.12M | -16.07M |
| EBITDA | - | - | - | - | - | - | - | - | - | -61.70M | 70.89M | -20.31M | -8.44M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 5.20M | 3.13M | 828.00K | 173.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | -67.51M | 67.18M | -21.14M | -8.61M |
| Tax Provision | - | - | - | - | - | - | - | - | - | -4.70M | 138.00K | 151.00K | 0 |
| Net Income | -46.81M | -5.87M | -32.62M | -29.99M | -25.06M | -12.47M | -53.71M | -55.19M | - | -62.81M | 67.04M | -21.29M | -8.61M |
| Diluted EPS | -139.47 | -2.69 | -2.68 | -1.58 | - | - | - | - | - | -11.76 | 11.12 | -3.52 | -1.36 |
| R&D Expense | 4.36M | 8.29M | 16.44M | 20.08M | 18.33M | 21.56M | 38.39M | 36.52M | 23.77M | 27.26M | 30.93M | 26.41M | 22.28M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 12.39M | 39.67M | 49.27M | 59.79M | 45.85M | 53.17M | 57.15M | 102.54M | - | 87.81M | 128.41M | 90.64M | 59.03M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 79.06M | 102.12M | 72.18M | 40.37M |
| Cash & Equivalents | 2.38M | 1.40M | 32.24M | 46.98M | 35.66M | 11.47M | 11.44M | 41.92M | 93.04M | - | 45.81M | 34.05M | 16.05M | 21.26M |
| Inventory | - | - | - | - | - | - | - | - | - | 463.00K | 899.00K | 0 | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | 861.00K | 2.10M | 0 | - | - |
| Total Liabilities | - | 33.34M | 6.24M | 7.32M | 24.97M | 24.44M | 21.95M | 44.26M | 79.78M | - | 84.58M | 55.45M | 35.57M | 9.65M |
| Current Liabilities | - | 18.48M | 5.35M | 6.66M | 3.72M | 10.14M | 5.88M | 11.01M | 26.40M | - | 17.62M | 16.30M | 24.10M | 5.73M |
| Long Term Debt | - | - | - | 0 | 14.25M | 10.30M | 15.08M | 0 | - | 40.35M | 45.39M | 12.16M | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | 48.60M | 15.08M | 16.27M | 2.17M |
| Total Equity | -65.42M | -108.11M | 33.43M | 41.95M | 34.82M | 21.41M | 31.23M | 12.89M | 22.76M | - | 3.23M | 72.96M | 55.08M | 49.38M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 4.09M | 4.65M | 4.75M | 5.44M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -9.47M | -24.55M | -29.35M | -24.56M | -28.32M | -38.12M | -49.35M | - | -79.88M | 60.16M | -24.01M | -5.28M |
| Investing Cash Flow | - | -488.00K | 1.59M | -22.47M | -9.62M | -803.00K | 26.24M | 6.47M | - | -27.39M | -34.88M | 6.15M | 24.31M |
| Financing Cash Flow | - | 40.80M | 37.70M | 40.50M | 9.99M | 29.42M | 42.30M | 94.00M | - | 48.60M | -36.72M | -139.00K | -14.17M |
| Capital Expenditure | -431.00K | -704.00K | -589.00K | -27.00K | -2.00K | -565.00K | -0 | -4.00K | -1.17M | -9.00K | - | - | - |
| Free Cash Flow | - | -10.18M | -25.13M | -29.38M | -24.56M | -28.89M | -38.12M | -49.36M | - | -79.89M | 60.16M | -24.01M | -5.28M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | -58.67M | -11.44M | -18.00M | 4.85M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 3.3% | 284.9% | - | - | - | - | - | - | - | 87.7% | 88.9% | 100.0% | - |
| Operating Margin % | -42.7% | -1,166.2% | -11,030.7% | -10,823.7% | -10,241.2% | -11,666.5% | -40,430.6% | - | - | -1,684.5% | 51.9% | -990.8% | -78.0% |
| Net Margin % | -277.7% | -467.1% | -12,693.8% | -11,668.9% | -9,751.0% | -4,851.4% | -44,388.4% | - | - | -1,233.7% | 47.8% | -568.3% | -41.8% |
| ROE % | 43.3% | -17.5% | -77.8% | -86.1% | -117.0% | -39.9% | -416.5% | -242.5% | - | -1,942.7% | 91.9% | -38.7% | -17.4% |
| ROCE % | 118.3% | -42.7% | -66.5% | -49.6% | -73.7% | -63.4% | -106.0% | -67.2% | - | -122.2% | 64.8% | -55.8% | -30.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SCYX
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Dose-optimization data from the Phase 1 study expected Q3 2026 to support Phase 2 proof-of-concept initiation in ADPKD in Q4 2026JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnol…
Upcoming Stock Splits This Week (June 1 to June 5) – Stay Invested
These are the upcoming stock splits for the week of June 1 to June 5, based on TipRanks’ Stock Splits Calendar. A stock split is a corporate move that increases the number of shares outstanding while reducing the price of each share proport…
SCYNEXIS Announces One-for-Eight Reverse Stock Split
SCYNEXIS’s Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026JERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”), a clinical-stage biotechnology company dedicated to advanci…
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
Completed transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD)A Phase 2 proof-of-concept study of SCY-770 in A…
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Au…
SCYNEXIS Enters $40 Million Private Placement, Completes Acquisition of PXL-770 to Treat Kidney Disease
SCYNEXIS (SCYX) said Tuesday that it has entered into a securities purchase agreement with investors
SCYX — Frequently Asked Questions
What is the current share price of SCYX?
As of 2026-08-05 17:25 PDT, SCYX trades at $5.16 on NASDAQ/NYSE. Its 52-week range is $3.57 to $9.44.
What is the market capitalisation of SCYX?
SCYX has a market capitalisation of $28.08M on NASDAQ/NYSE.
What is the P/E ratio of SCYX?
SCYX trades at a trailing price-to-earnings (P/E) ratio of -3.79. Its price-to-book (P/B) ratio is 0.57.
What is the return on equity (ROE) of SCYX?
SCYX has a return on equity (ROE) of -17.44%. Its return on capital employed (ROCE) is -30.16%.
Is SCYX a good stock to buy?
This page provides a data-driven analysis of SCYX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.